2023-2025 Research Funding Competition

SCN’s national research funding competition supports world-class, translational, regenerative medicine research, across the research continuum, to facilitate health, social and economic benefits for Canadians.

The application process for Round 2 is open and offers 22-month awards. 

On September 1, the Stem Cell Network launched the second and final of two national research funding competitions planned for SCN’s 2022-2025 funding cycle. This new competition will support research activities during the 2023 to 2025 time period. Five regenerative medicine research programs are available that focus on innovation, clinical translation, policy and societal impact, and commercialization.

The results from SCN’s Round 1 2022-2025 competition, which offered two and three-year awards, were announced publicly on May 12, 2022, and can be found here.

Letter of Intent instructions for ProposalCentral

A Letter of Intent (LOI) submission is mandatory for all SCN funding programs. Please review the LOI instructions. LOIs will be used to identify peer review requirements, gauge the level of interest in SCN’s programs, and ensure projects fall within SCN’s regenerative medicine mandate.

  • Impact Awards: ELSI Stream ONLY – Letter of Intent submission DEADLINE EXTENDED to Wednesday, October 12 at 11:59 p.m. PT
  • Letter of Intent submissions open on Thursday, September 1, 2022.
  • Letter of Intent submission deadline is Thursday, September 22, 2022, at 11:59 p.m. PT
  • Full application submission will be opened to eligible LOI submitters on Tuesday, September 27, 2022.
  • Full application submission deadline is Thursday, December 1, 2022, at 5:00 p.m. ET (2:00 p.m. PT)

The five programs are:

Impact Awards
SCN will provide up to $250,000 to support proof-of-principle experiments, including novel therapeutic or technical approach development that will drive regenerative medicine therapies forward.

Impact Awards: ELSI Stream ONLY – Letter of Intent submission DEADLINE EXTENDED to Wednesday, October 12 at 11:59 p.m. PT
SCN will provide up to $200,000 to support the knowledge generation and/or translation of regenerative medicine research for targeted stakeholders and/or users.

Accelerating Clinical Translation Award
SCN will provide up to $600,000 to support multi-disciplinary research that is moving towards the clinic within five years; or is addressing a key research question associated with an ongoing clinical trial.

Clinical Trial Awards
SCN will provide up to $750,000 to support early-stage clinical trial projects with high translational potential.

Fueling Biotechnology Partnerships Awards
SCN will provide up to $400,000 to support academic partnerships with emerging Canadian regenerative medicine biotechnology companies to bring innovative technologies or therapies to the clinic or market.

How to Apply:

SCN has modernized its funding application process and all applications must be submitted via an online application process hosted through the ProposalCentral application portal. All investigators (Lead and Co-investigators) on a team should register and open an account on ProposalCentral prior to initiating an application. ProposalCentral accounts are not required for collaborators or highly qualified personnel (HQP; e.g. graduate students, post-doctoral fellows, technicians or research associates). The lead-investigator’s institutional signing authorities (e.g department or grants administrators) are also required to have a ProposalCentral account in order to sign-off on the submission of the full application.

Additional ProprosalCentral resources (available in English only):



LOI and full application-related questions should be addressed to Jon Draper (